Inhibition of PrPScformation in scrapie infected N2a cells by 5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine derivatives

• DOI: 10.4161/pri.21913
• Publication Date: 2012-11-20T16:41:24Z
• Authors: Fani Koukouli; Ioannis Paspaltsis; Evgenia Salta; Konstantinos Xant...; Eftychia N. Koini; Theodora Calogero...; Theodoros Sklaviadis
• Keywords: 0301 basic medicine; Mice; 03 medical and health sciences; PrPSc Proteins; Cell Line, Tumor; Animals; PrPC Proteins; Benzoxazines; Scrapie; 3. Good health

Prion diseases are fatal, neurodegenerative diseases characterized by the structural conversion of the normal, cellular prion protein, PrP (C) into an abnormally structured, aggregated and partially protease-resistant isoform, termed PrP (Sc) . Although substantial research has been directed toward development of therapeutics targeting prions, there is still no curative treatment for the disease. Benzoxazines are bicyclic heterocyclic compounds possessing several pharmaceutically important properties, including neuroprotection and reactive oxygen species scavenging. In an effort to identify novel inhibitors of prion formation, several 5,7,8-trimethyl-1,4-benzoxazine derivatives were evaluated in vitro for their effectiveness on the expression levels of normal PrP (C) and its conversion to the abnormal isoforms of PrP (Sc) in a scrapie-infected cell culture model. The most potent compound was 2-(4-methoxyphenyl)-5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine, with a diminishing effect on the formation of PrP (Sc) , thus establishing a class of compounds with a promising therapeutic use against prion diseases.